Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)

BACKGROUND: Advances in multi-modality treatment of locally advanced rectal cancer (LARC) have resulted in low local recurrence rates, but around 30% of patients will still die from distant metastatic disease. In parallel, there is increasing recognition that with radiotherapy and systemic treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanna, Catherine R., O’Cathail, Sean M., Graham, Janet S., Saunders, Mark, Samuel, Leslie, Harrison, Mark, Devlin, Lynsey, Edwards, Joanne, Gaya, Daniel R., Kelly, Caroline A., Lewsley, Liz-Anne, Maka, Noori, Morrison, Paula, Dinnett, Louise, Dillon, Susan, Gourlay, Jacqueline, Platt, Jonathan J., Thomson, Fiona, Adams, Richard A., Roxburgh, Campbell S. D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393812/
https://www.ncbi.nlm.nih.gov/pubmed/34446053
http://dx.doi.org/10.1186/s13014-021-01888-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393812/
https://www.ncbi.nlm.nih.gov/pubmed/34446053
http://dx.doi.org/10.1186/s13014-021-01888-1

Ejemplares similares